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Proinsulin, GLP-1, and glucagon are
associated with partial remission in children
and adolescents with newly diagnosed type
1 diabetes
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behalf of The Hvidoere Study Group on childhood diabetes. Proinsulin,
GLP-1, and glucagon are associated with partial remission in children and
adolescents with newly diagnosed type 1 diabetes.
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Objective: Proinsulin is a marker of beta-cell distress and dysfunction in type
2 diabetes and transplanted islets. Proinsulin levels are elevated in patients
newly diagnosed with type 1 diabetes. Our aim was to assess the relationship
between proinsulin, insulin dose-adjusted haemoglobin A1c (IDAA1C),
glucagon-like peptide-1 (GLP-1), glucagon, and remission status the first year
after diagnosis of type 1 diabetes.
Methods: Juvenile patients (n = 275) were followed 1, 6, and 12 months after
diagnosis. At each visit, partial remission was defined as IDAA1C ≤9%. The
patients had a liquid meal test at the 1-, 6-, and 12-month visits, which
included measurement of C-peptide, proinsulin, GLP-1, glucagon, and insulin
antibodies (IA).
Results: Patients in remission at 6 and 12 months had significantly higher
levels of proinsulin compared to non-remitting patients (p < 0.0001,
p = 0.0002). An inverse association between proinsulin and IDAA1C was
found at 1 and 6 months (p = 0.0008, p = 0.0022). Proinsulin was positively
associated with C-peptide (p < 0.0001) and IA (p = 0.0024, p = 0.0068,
p < 0.0001) at 1, 6, and 12 months. Glucagon (p < 0.0001 and p < 0.02) as
well as GLP-1 (p = 0.0001 and p = 0.002) were significantly lower in remitters
than in non-remitters at 6 and 12 months. Proinsulin associated positively with
GLP-1 at 1 month (p = 0.004) and negatively at 6 (p = 0.002) and 12 months
(p = 0.0002).
Conclusions: In type 1 diabetes, patients in partial remission have higher
levels of proinsulin together with lower levels of GLP-1 and glucagon
compared to patients not in remission. In new onset type 1 diabetes proinsulin
level may be a sign of better residual beta-cell function.
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Type 1 diabetes is a T-cell-mediated autoimmune
disease characterised by destruction of the insulin-
producing beta cells (1). After disease diagnosis, a vari-
able amount of beta-cell mass is still functioning and
some insulin is released together with C-peptide and
uncleaved proinsulin. Elevated levels of proinsulin are
seen in islet transplanted and type 2 diabetic patients.
This is thought to be a result of impaired processing
of proinsulin and therefore considered as a marker of
stressed beta cells (2–5). The role of proinsulin in type 1
diabetes is more controversial; is proinsulin a marker of
impaired/stressed beta cells or is it a marker of residual
beta-cell function with good metabolic control and par-
tial remission? Proinsulin has been shown to be elevated
before diagnosis of type 1 diabetes and in first-degree
relatives of type 1 diabetic patients (6, 7). This increase
might be caused by cytokine-induced infiltration of the
immune cells (8). Proinsulin is elevated throughout the
first year of type 1 diabetes, both absolute and relative
to C-peptide (9, 10). The circulating concentrations of
proinsulin seem to evolve differently from C-peptide. A
peak in proinsulin has been reported around 6 months
after diagnosis, whereas C-peptide achieves the highest
level at 3 months (9, 11). The difference in proinsulin/C-
peptide ratio has been explained by impaired proinsulin
processing or by circulating insulin antibodies (IA),
which are thought to bind proinsulin and thereby
reduce the metabolic clearance rate (9, 10, 12, 13).
A low proinsulin/C-peptide ratio has been associated
with a long remission phase in children, while high
levels of proinsulin was associated to remission [insulin
dose ≤0.3 U/kg/24 h and haemoglobin A1c (HbA1c)
≤5.5% (37 mmol/mol)] in adults (9, 12, 14). A possi-
ble association between proinsulin concentrations and
remission status has not been investigated in paediatric
patients.
In type 1 diabetes, the inappropriate elevation of
glucagon during hyperglycaemia has been attributed
to the lack of intra-islet insulin to restrict glucose’s
effect on the alpha cell (14, 15). It is therefore rele-
vant to investigate the effect of insulin deficiency on
glucagon secretion when studying the metabolic sta-
tus of newly diagnosed type 1 diabetic patients. In
addition, the gastrointestinal hormone glucagon-like
peptide-1 (GLP-1) could be an important player in
the remission phase of type 1 diabetes. GLP-1 has
been shown to stimulate beta-cell proliferation in vitro,
enhance beta-cell neoformation following partial pan-
createctomy, protect beta cell against cytokine-induced
apoptosis, enhance beta-cell replication, and stimulate
insulin release in a glucose dependent way (16, 17).
The aim of our study was therefore to investigate
the relationship between remission status and meal-
stimulated proinsulin, C-peptide, GLP-1, and glucagon
plasma concentrations in a cohort of children and
adolescents during the first 12 months after diagnosis
with type 1 diabetes. We tested if proinsulin, GLP-1, or
glucagon measured at 1 month could predict remission
status at 6 and 12 months. In addition, we examined
the relationship between proinsulin, glycaemic control,
and IA together with GLP-1 and glucagon.
Methods
Subjects
The Hvidoere Remission Phase Study is a prospective,
long-term observational study conducted in 18 cen-
tres representing 15 countries in Europe and Japan.
Between August 1999 and December 2000, 275 newly
diagnosed patients (48% male, all less than 16 yr old)
were recruited to the study. Clinical data (gender, dura-
tion of symptoms, height, weight, and metabolic status)
were collected at the first hospital visit. The Hvidoere
cohort has previously been described in details (11).
Proinsulin and C-peptide
To estimate the residual beta-cell function (C-peptide
and proinsulin) a liquid-meal Boost™-test [6 mL/kg
(max: 360 mL, Mead Johnson, Evansville, IN, USA;
237 mL = 8 FL OZ contains 33 g carbohydrate, 15 g
protein, and 6 g fat, a total of 240 kcal)] was carried out
at 1, 6, and 12 months (± 1wk) after diagnosis. Of the
patients, 133 girls and 129 boys contributed with at least
one measurement (95% of total). Serum C-peptide was
analysed by a fluoroimmunometric assay as described
previously (18).
Mixed meal-stimulated proinsulin was analysed
by a sandwich enzyme-linked immunosorbent assay
using two monoclonal antibodies: Coating antibody:
PEP-001 (Novo Nordisk a/s, Bagsværd, Denmark).
Detecting antibody: HUI-001 (Novo Nordisk a/s,
Bagsværd, Denmark), biotinylation performed as
described by Berger et al. Streptavidin-peroxidase con-
jugate (Kirkegaard and Perry Laboratories, Gaithers-
burg, MD, USA). The assay detects total proinsulin as
well as the four metabolites: split(32–33), des(31–329),
split(65–66), and des(64–65)-proinsulin. This assay
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has no cross reactivity with insulin, C-peptide, insulin-
like growth factor-I (IGF-I), and IGF-II. The detection
limit was 0.3 pmol/L (‘0’-response + 3 × SD), and the
analytical range was 0.3–100 pmol/L. Inter-assay pre-
cision was total inter-assay coefficient of variation (CV)
4.7–8.7%.
Insulin antibody
IA was measured 1, 6, and 12 months after diagnosis.
The antibodies were analysed centrally by methods
described previously (11). The results were expressed
as relative units (RU).
GLP-1 and glucagon
Glucagon and GLP-1 concentrations in plasma sam-
pled at 90 min were measured after extraction of plasma
with 70% ethanol (vol/vol, final concentration). The
glucagon RIA was directed against the C terminus of
the glucagon molecule (antibody code no. 4305) and
therefore mainly measures glucagon of pancreatic ori-
gin (19). The plasma concentrations of GLP-1 were
measured against standards of synthetic GLP-1(7–36)
amide using antiserum code no. 89390, which is specific
for the amidated C terminus of GLP-1 and there-
fore mainly reacts with GLP-1 of intestinal origin.
The assay reacts equally with intact GLP-1 and with
GLP-1(3–36) amide, the primary metabolite. Because
of the rapid and intra-vascular conversion of GLP-1
to their primary metabolites, it is essential to deter-
mine both the intact hormone and the metabolite for
estimation of the rate of secretion of GLP-1 (20). For
both assays, sensitivity was less than 1 pmol/L, intra-
assay CV less than 6% at 20 pmol/L, and recovery of
standard, added to plasma before extraction, about
100% when corrected for losses inherent in the plasma
extraction procedure (21). All measurements were done
centrally immediately after data collection ended in
year 2000.
HbA1c, insulin dose-adjusted HbA1c and partial
remission
Insulin dose-adjusted HbA1c (IDAA1C) is an
HbA1c and insulin weighted indirect measure of
residual beta-cell function. HbA1c was analysed
at the Steno Diabetes Centre using the Bio-Rad
HbA1c sample preparation kit (Bio-Rad Laboratories,
Munich, Germany). HbA1c analysis was performed
by automatic high-pressure liquid chromatography
with the same calibrator lots as used in the diabetes
control and complications trial (DCCT) to facilitate
comparisons. Normal range for the Steno method was
4.4–6.3% (about 0.3% higher than the DCCT method).
IDAA1C is calculated on basis of the actual insulin
dose and HbA1c as IDAA1C = HbA1c (percent) +
[4 × insulin dose (U/kg/24 h)]. At each visit, partial
remission was defined as an IDAA1C ≤9 correspond-
ing to a predicted C-peptide response of >300 pmol/L
for the corresponding stimulated C-peptide (22). At 1,
6, and 12 months 248, 231, and 230 of the patients had
data available for calculating IDAA1C. Partial remis-
sion defined by IDAA1C has better stability compared
with the existing definitions (22).
Statistical methods
Data are presented as median and range for parameters
not normally distributed and mean ± SD for nor-
mally distributed parameters. C-peptide, proinsulin,
IA, GLP-1, and glucagon were all studied on log-
arithmic scale. The associations between proinsulin
and C-peptide and between proinsulin and IA were
investigated by regression analysis with proinsulin as
dependent variable accounting for gender and age, 1,
6, and 12 months after diagnosis. A prediction analysis
to evaluate if proinsulin measured at 1 and 6 months
could give information of C-peptide at 12 months was
performed using multiple regression accounting for
age and gender. The relation between proinsulin and
glycaemic control was investigated by regression anal-
ysis with IDAA1C as dependent variable accounting
for gender, age, and C-peptide 1, 6, and 12 months
after diagnosis. The differences in mean values of
proinsulin, GLP-1, and glucagon between remitters
and non-remitters were analysed by the nonparamet-
ric Kruskal–Wallis test for not normally distributed
parameters. To test if 1-month measurements could
predict remission status at 6 and 12 months prediction
analyses were performed. We used logistic regression
analyses accounting for gender, age, and stimulated
blood glucose. The relation between GLP-1 and proin-
sulin was investigated by regression analysis with
proinsulin as dependent variables accounting for gen-
der, age, IA, and C-peptide, 1, 6, and 12 months after
diagnosis. The results are presented with estimates,
converted into the effect of a 10% change of the inde-
pendent variable ± confidence interval of the change.
A p-value of <0.05 is considered significant. The analy-
ses were performed using sas version 9.1 (SAS Institute
Inc., Cary, NC, USA).
Results
Proinsulin, glycaemic control, C-peptide, and IA
Among all the patients the median level of stim-
ulated proinsulin increased from 1 month (22.80
pmol/L range: 1.90–297.00 pmol/L) to 6 months (38.85
pmol/L range: 0.03–476.00 pmol/L), but subsequently
decreased from 6 to 12 month (25.20 pmol/L range:
0.03–558.00 pmol/L). The median level of stimu-
lated C-peptide decreased from baseline (1 month) to
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Fig. 1. The mean levels (log(10) scale) of stimulated proinsulin
pmol/L (-), C-peptide pmol/l (- -), and IA relative units (RU) (...) at
1, 6, and 12 months after diagnosis. Proinsulin levels increase from 1
to 6 months but decrease from 6 to 12 months, while C-peptide level
declines throughout all time points. IA levels increase throughout all
time points.
12 months after disease onset (1 month: 409.50 pmol/L
range: 10.00–2040.00 pmol/L, 6 months: 287.00
pmol/L range 10.00–1663.00 pmol/L, 12 months:
206.00 pmol/L range: 10.00–2721.00 pmol/L). IA
increased because of the introduction of exoge-
nous insulin treatment throughout the study period
[1 month: median with range: 12.91 RU (0-588.91),
6 months: 117.51 RU (0-3005.98), 12 months: 181.98
RU (0-3143.28)] (Fig. 1).
As expected, analyses showed a positive significant
association between proinsulin and C-peptide at all
time points; 1 month (estimate: 0.54, p < 0.0001) sug-
gesting 5.3% (3.9–6.7%) higher C-peptide by a 10%
increase in proinsulin, 6 months (estimate: 0.39, p <
0.0001) suggesting 3.8% (2.9–4.8%) higher C-peptide
by a 10% increase in proinsulin, and 12 months (esti-
mate: 0.46, p < 0.0001) suggesting 4.4% (3.6–5.3%)
higher C-peptide by a 10% increase in proinsulin, when
adjusted for gender and age. There was a positive sig-
nificant association between proinsulin and IA at all
time points (estimate: 0.10, p = 0.002, estimate: 0.15,
p = 0.007, and estimate: 0.21 p < 0.0001) suggesting
0.9% (0.3–1.5); 1.4% (0.4–2.5); and 2.0% (1.0–3.0)
higher proinsulin level by a 10% increase in IA at 1, 6,
and 12 months after diagnosis, respectively.
We found a negative significant association between
IDAA1C and proinsulin at 1 and 6 months (estimate:
−0.66, p = 0.0008 and estimate: −0.39, p = 0.0022)
suggesting 6.1% (2.6–9.5) and 3.7% (1.4–5.9) lower
IDAA1C by a 10% increase in proinsulin, respectively.
Prediction analyses showed that the best predictor of
C-peptide at 12 months was C-peptide at 6 months
(estimate: 0.70, p < 0.0001) suggesting 6.8% (5.1–8.7)
higher C-peptide at 12 months by a 10% increase in
C-peptide after 6 months. However, in addition to
C-peptide total proinsulin at 6 months had a significant
predictive value on C-peptide at 12 months (estimate:
0.14 (p = 0.03) suggesting 1.4% higher C-peptide at
12 months by a 10% increase in proinsulin after
6 months.
Remission status related to proinsulin, GLP-1, and
glucagon levels
Remission status was defined at 1, 6, and 12 months
after diagnosis in all patients with complete data avail-
able for calculating the IDAA1C (HbA1c and insulin
dose). At 1 month, 35 patients (14.1%) were in par-
tial remission (IDAA1C ≤9), at 6 months 104 (45.0%),
and at 12 months, 41 (17.8%) of the patients were
in partial remission (Table 1). Analysis revealed that
patients in remission had higher levels of proinsulin
compared to patients not in remission at all time
points. This difference was not significant at 1 month,
whilst it was highly significant at 6 (p < 0.0001), and
12 months (p = 0.0002), after diagnosis. Also, GLP-1
and glucagon levels differed significantly between
patients in remission and patients not in remission.
Patients in remission had significantly lower levels of
GLP-1 and Glucagon compared to patients not in
remission at both 6 and 12 months (Table1). No sta-
tistically significant difference was found at 1 month
after diagnosis for both variables. Prediction analyses
using the 1 month measurements revealed that proin-
sulin and GLP-1 could predict remission status at
6 month, suggesting 6.7% (1.8–11.7%) better possibil-
ity for remission at 6 months by a 10% increase in
proinsulin at 1 month (estimate: 0.68, p = 0.005), 8.5%
(3.2–13.5%) lower possibility for being in remission
at 6 months by a 10% increase in GLP-1 at 1 month
(estimate: −0.93, p = 0.001) and 16.9% (8.6–24.5%)
lower possibility for remission at 6 months by a 10%
increase in stimulated glucose at 1 month (estimate:
−1.95, p < 0.0001). There was no effect of age, gender,
and glucagon (Table 2). At 12 months after diagnosis
only glucagon and stimulated blood glucose measured
at 1 month could predict remission status, suggesting
6.2% (1.0–11.2%) lower possibility for remission by a
10% increase in glucagon at 1 month (estimate: −0.67,
p = 0.02) and 12.0% (3.0–20.1%) lower possibility for
remission by a 10% increase in stimulated blood glu-
cose (estimate: −1.33, p = 0.009). At this time point
age, gender, proinsulin, and GLP-1 no longer had any
predictive power (Table 2).
Relationship between proinsulin and GLP-1
Multiple regression analyses showed that proinsulin
was significantly positively associated with GLP-1
at 1 month (estimate: 0.22, p = 0.004) suggesting
2.1% (0.7–3.5) higher proinsulin level by a 10%
increase in GLP-1 and significantly negatively asso-
ciated with GLP-1 at 6 and 12 months after diagnosis
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Table 1. Concentrations of proinsulin, C-peptide, GLP-1, and glucagon (median with range) at 1, 6, and 12months among
patients in remission and patients not in remission at the three different time points
Patients in partial remission Patients not in partial remission p Values
1month
Number 35 (14.11%) 213 (85.89%)
Proinsulin (pmol/L) 31.50 (6.90–297) 22.00 (1.90–136.00) NS
C-peptide (pmol/L) 457.00 (22.00–1620.00) 392.00 (10.00–2040.00) NS
GLP-1 (pmol/L) 18.00 (3.00–65.00) 17.00 (4.00–134.00) NS
Glucagon (pmol/L) 10.00 (2.50–22.00) 9.00 (2.50–34.00) NS
6months*
Number 104.00 (45.04%) 127 (54.96%)
Proinsulin (pmol/L) 58.8 (3.60–476.00) 23.90 (0.03–474.00) <0.0001
C-peptide (pmol/L) 414.00 (26.00–1663.00) 233.00 (10.00–1600.00) <0.0001
GLP-1 (pmol/L) 16.00 (4.00–62.00) 22.00 (1.00–68.00) 0.0001
Glucagon (pmol/L) 10.00 (2.50–31.00) 12.00 (2.50–28.00) <0.0001
12months*
Number 41 (17.83%) 189 (82.17%)
Proinsulin (pmol/L) 38.5 (0.20–204.00) 21.2 (0.03–558.00) 0.0002
C-peptide (pmol/L) 417.00 (10.00–1364.00) 178.00 (1.00–2721.00) <0.0001
GLP-1 (pmol/L) 19.00 (6.00–66.00) 24.00 (5.00–64.00) 0.002
Glucagon (pmol/L) 11.00 (2.50–23.00) 13.00 (2.50–58.00) 0.02
GLP-1, glucagon-like peptide-1; NS, not significant.
*The parameters differed significantly between patients in remission and patients not in remission by use of the nonparametric
Kruskal–Wallis test.
Table 2. Results of the prediction analysis on remission
status (IDDA1c ≤9)
6Months 12MonthsContribution of
1month
measurements* Est. p Est. p
Age −0.0388 NS 0.0570 NS
Sex −0.3179 NS −0.7936 NS
Ln (proinsulin)* 0.6780 0.005 0.4248 NS
Ln (GLP-1)* −0.9283 0.001 −0.0638 NS
Ln (Glucagon)* −0.2318 NS −0.6724 0.02
Ln (stim. BG)* −1.9457 <0.0001 −1.3347 0.009
Est, estimate; GLP-1, glucagon-like peptide-1; IDAA1c,
insulin dose-adjusted haemoglobin A1c; NS, not significant;
stim. BG, stimulated blood glucose.
Results of the prediction analyses on remission status
(IDAA1c ≤9) at 6 and 12months after diagnosis with type 1
diabetes are shown in the table.
Age, gender, and the 1-month measurements of proinsulin,
GLP-1, glucagon, and stimulated blood glucose are used as
covariates.
(estimate: −0.33, p = 0.004 and estimate: −0.50, p =
0.0009) suggesting 3.1% (1.0–5.1) and 4.5% (1.9–7.1)
lower proinsulin level by a 10% increase in GLP-1,
respectively (Fig. 2).
Discussion
We investigated the association between partial clini-
cal remission in children with newly diagnosed type 1
diabetes and levels of proinsulin, GLP-1, and glucagon.
Patients in remission at 6 and 12 months after diag-
nosis have significantly higher proinsulin compared
to patients not in remission. A possible explanation
could be that higher circulating levels of proinsulin,
which is a primary autoantigen in type 1 diabetes,
might generate more regulatory T-cells (Tregs) fol-
lowed by a relative hyposensibilisation towards this
autoantigen and a slower autoimmune destruction
of the beta cells (23) in the same way as immunisa-
tion with L7–24 peptide from preproinsulin has been
shown to induce Tregs and significantly reduce diabetes
incidence in non-obese diabetic mice (24). Previously,
another study has shown a positive association between
remission and proinsulin levels in an adult population,
where partial remission was defined as an insulin dose
≤0.3 U/kg/24 h and HbA1c ≤5.5% (37 mmol/mol) at
a given time point. We confirm this finding in a pae-
diatric population using IDAA1C as a measure of
remission. IDAA1C has proven to be a very stable
definition of remission. It is expected that the num-
ber of patients in remission increases between 1 and
6 months, independent of remission definition, how-
ever, only one patient entered remission between 6
and 12 months when IDAA1C was used to define
remission in this cohort (22). In addition, we used
a standardised liquid-meal Boost™-test to obtain stim-
ulated values of proinsulin. In line with that, we report
a significant association between proinsulin and good
metabolic control, as assessed by IDAA1C. The rela-
tion between proinsulin and C-peptide in our cohort
is in consensus with previous reports (9, 11). Serum
concentrations of proinsulin peaked at 6 months, while
C-peptide declined from 1 to 6 months. As stimulated
C-peptide has been described to be the best measure
of preserved beta-cell function (25), it is interesting to
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Fig. 2. The association between proinsulin and glucagon-like peptide-1 (GLP-1) levels at 1 (-), 6 (- – -), and 12 (---) months after diagnosis.
note that while the residual beta-cell function decline
the level of proinsulin increases. This could indicate
that proinsulin processing is not functioning well and
that the remaining cells could be under elevated phys-
iological stress. It has, however, been suggested that
binding of proinsulin by IA is the explanation for the
change of C-peptide/proinsulin ratio after diagnosis of
the disease (9, 12). As opposed to that, our data show
an increase in IA from 6 to 12 months, which most
likely is a result of insulin treatment, while proinsulin
declines in the same time period. It is not possible to
make a firm conclusion from our data on whether the
proinsulin C-peptide relationship reflects stressed beta
cells, and further investigations are needed to elucidate
this. However, proinsulin (6 months) has a predictive
effect on later C-peptide (12 months) and we find that
proinsulin measured at 1 month could predict remis-
sion status at 6 months. This indicates that proinsulin
could be regarded as an important future endpoint.
Glucagon levels were lower among patients in remis-
sion compared to patients not in remission at 6 and
12 months, and glucagon measured at 1 month could
predict remission status after 12 months. This fits very
well with our previous publication on the intra-islet
hypothesis, where we propose that glucagon secretion
is stimulated by postprandial glucose in an islet envi-
ronment where the beta cells no longer produce insulin
and thereby have no inhibitory effect on the alpha
cells (21). In this study, the hypothesis proves its value
in regards to remission status. Patients in partial remis-
sion still produce insulin after meal stimulation and
glucagon secretion is inhibited.
GLP-1 differed significantly between patients in
remission and not in remission, with lower levels found
in remitting patients at 6 and 12 months after disease
onset. Proinsulin and GLP-1 associated positively at
1 month but inversely at 6 and 12 months. As we have
previously shown that GLP-1 associate positively with
postprandial glucose, this could be expected, but the
results are also in consensus with a previous study
showing that GLP-1 can reverse the anti-proliferative
effect mediated by inflammatory cytokines such as
IFNg in rat islets (26). Thus, it could be speculated that
the cytokine inflammation is less aggressive in patients
in remission and that GLP-1 level as a response to
that is lower. Further, it is very interesting that GLP-1
measured at 1 month could predict remission status at
6 months, even when there was adjusted for postpran-
dial glucose in the analyses. This could indicate that
the actions of GLP-1 do influence partial remission.
The shift in proinsulin and GLP-1 association between
1 and 6 months might relate to a gradual improvement
of the residual beta-cell function in this period.
High levels of proinsulin and low levels of GLP-1
resemble the pattern seen in patients with type 2 dia-
betes before treatment or with poor metabolic disease
status (3). Several reports have shown that incretin-
based therapies to type 2 diabetic patients lowers
proinsulin level and HbA1c, which leads to a bet-
ter metabolic control (17, 27–29). Keeping in mind
that type 2 diabetic patients display a very low grate
immunological inflammation in the islets, it could be
speculated that islets of type 1 diabetic patients in clin-
ical partial remission resemble the islet-condition of
type 2 diabetes – a disease condition where the islets
are somehow protected against immunologic-induced
killing of the beta cells. We propose that high proinsulin
and low GLP-1 could be a marker of this.
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Several reports suggest treating prediabetic or newly
diagnosed type 1 diabetic patients with GLP-1 (27, 30,
31). Based on our data it could be speculated that the
potential effect of GLP-1 on proinsulin/C-peptide ratio
would be important to take in to consideration. To our
knowledge this is the first report that describes both
a significant relation between proinsulin and GLP-1,
and between remission status and GLP-1.
In conclusion, our data suggest that proinsulin,
GLP-1, and glucagon are significantly associated with
partial clinical remission, patients in remission having
higher proinsulin and lower GLP-1 and glucagon levels
compared to patients not in remission. In addition,
proinsulin associate positively with C-peptide and
inversely with IDAA1C, which could point to, that
in our cohort of juvenile patients with newly diagnosed
type 1 diabetes, relatively high levels of proinsulin
could be regarded as a marker of a slower disease
progression.
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